Achilles Therapeutics (ACHL) AI Stock Analysis

• Market Cap: $60.83M
• Dividend Yield: N/A
• Average Volume (3M): 1.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 204
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 41,088,000
• 10 Day Avg. Volume: 1,029,946
• 30 Day Avg. Volume: 1,836,713
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 8.71
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Achilles Therapeutics' overall score reflects its financial challenges in line with typical pre-commercial biotech firms, offset by positive technical indicators. While technical momentum is strong, lack of revenue and traditional valuation metrics, combined with limited earnings call insights, contribute to a balanced score.

Achilles Therapeutics Business Overview & Revenue Model

Company Description

Achilles Therapeutics (ACHL) is a biopharmaceutical company focused on the development of precision T cell therapies to treat various types of cancer. The company leverages its proprietary technology platform to identify and target clonal neoantigens, unique mutations present in a patient's cancer cells, which enables the creation of personalized T cell therapies tailored to each individual's tumor profile. Achilles Therapeutics operates within the biotechnology and healthcare sectors, aiming to revolutionize cancer treatment through its innovative approach to immunotherapy.

How the Company Makes Money

Achilles Therapeutics generates revenue primarily through the development and commercialization of its T cell therapies. The company aims to bring its therapeutic products to market by advancing them through clinical trials and obtaining regulatory approvals. Revenue streams may include licensing agreements, collaboration partnerships with larger pharmaceutical companies, and potential milestone payments or royalties from successful commercialization of its therapies. Additionally, Achilles Therapeutics may engage in research and development collaborations that provide funding and resources in exchange for access to its proprietary technology platform. These collaborations and partnerships are significant contributors to its earnings, helping to finance further research and development activities.

Achilles Therapeutics Financial Statement Overview

Summary

Achilles Therapeutics faces typical pre-commercial biotech challenges, with zero revenue and widening net losses. The balance sheet shows stability in equity with low debt, but declining assets and equity reflect strain. Negative cash flows highlight the need for further financing.

Income Statement

Achilles Therapeutics has consistently reported zero revenue over the past years, indicating a lack of commercialized products. The company shows a widening net loss, with a significant negative net profit margin. Despite improvements in EBITDA margin, the overall income statement reflects financial challenges typical in biotech firms pre-commercialization.

Balance Sheet

The balance sheet reveals a stable equity position with a low debt-to-equity ratio, suggesting conservative financial leverage. However, the declining stockholders' equity and total assets over the years reflect financial strain. The equity ratio remains strong, indicative of shareholder investment stability despite ongoing losses.

Cash Flow

Achilles Therapeutics has negative operating and free cash flows, which are common in pre-revenue biotech companies. The free cash flow growth rate suggests further cash burn, while the operating cash flow to net income ratio indicates significant cash outflows relative to earnings, reflecting the need for continued financing to sustain operations.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-4.73M	-3.69M	-3.29M	-778.00K	-303.25K
	EBIT
-75.25M	-78.38M	-64.19M	-33.73M	-13.78M
	EBITDA
-70.44M	-78.38M	-57.77M	-32.95M	-13.47M
	Net Income Common Stockholders
-69.67M	-71.18M	-61.10M	-33.20M	-13.99M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
131.54M	173.34M	266.32M	177.85M	97.59M
	Total Assets
161.46M	220.36M	317.11M	218.92M	105.20M
	Total Debt
4.62M	8.58M	12.26M	15.98M	487.00K
	Net Debt
-126.92M	-164.76M	-254.06M	-161.87M	-97.11M
	Total Liabilities
19.09M	23.31M	27.58M	29.55M	3.86M
	Stockholders Equity
142.37M	197.04M	289.53M	189.37M	101.35M
Cash Flow		Free Cash Flow
-49.55M	-67.05M	-66.92M	-37.10M	-15.08M
	Operating Cash Flow
-48.45M	-59.53M	-59.28M	-25.25M	-14.14M
	Investing Cash Flow
-1.10M	-7.51M	-7.63M	-11.85M	-942.00K
	Financing Cash Flow
9.00K	1.00K	160.75K	113.70M	93.62M

Achilles Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACHL, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.33, and above the 200-day MA of 1.03, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 74.97 is Negative, neither overbought nor oversold. The STOCH value of 75.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACHL.

Achilles Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.35B	3.41	-40.83%	2.89%	18.11%	2.60%
ACHL	50 Neutral	$60.83M	―	-52.41%	―	―	―
FATE	48 Neutral	$143.25M	―	-54.21%	―	-78.55%	-0.92%
IOVA	48 Neutral	$1.18B	―	-57.48%	―	13698.99%	31.46%
ADAP	45 Neutral	$70.92M	―	-273.36%	―	194.23%	45.50%
IMTX	44 Neutral	$579.79M	59.18	3.73%	―	188.64%	―
KPTI	34 Underperform	$52.02M	―	41.08%	―	-0.55%	49.85%